RNS Number : 6057L Renalytix AI PLC 13 January 2021   Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders

Creates Pathway for Beneficiary Access to KidneyIntelX for Medicare Beneficiary Kidney Disease Populations NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) -- The Centers for Medicaid & Medicare (CMS) announced the establishment of the Medicare Coverage of Innovative Technology (MCIT) pathway ( RIN:

RNS Number : 4713L Renalytix AI PLC 13 January 2021   This announcement contains inside information   Renalytix AI plc (" RenalytixAI " or the " Company ")   Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics  

RNS Number : 6755K Renalytix AI PLC 05 January 2021   Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension

RNS Number : 6733K Renalytix AI PLC 05 January 2021   Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders

First-of-its-kind program combines early risk assessment of kidney decline and comprehensive care management to help slow kidney disease progression, improve care coordination and reduce costs NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kidney care innovators Renalytix AI (NASDAQ:RNLX, LSE:RENX)

RNS Number : 5211K Renalytix AI PLC 05 January 2021   This announcement contains inside information   Renalytix AI plc (" RenalytixAI " or the " Company ")   Early Risk Identification at Core of Innovative Kidney Care Partnership Between RenalytixAI, DaVita   First-of-its-kind program combines

NEW YORK, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today announced the

RNS Number : 3438K Renalytix AI PLC 04 January 2021     Renalytix AI plc (" RenalytixAI " or the " Company ")   RenalytixAI to Present at the 39 th Annual J.P. Morgan Healthcare Conference     NEW YORK , 4 January 2021 - Renalytix AI plc   (LSE : RENX) (NASDAQ: RNLX), an artificial

RNS Number : 8167H Renalytix AI PLC 07 December 2020     Renalytix AI plc (" RenalytixAI " or the " Company ")   Result of AGM   Renalytix AI plc   (LSE : RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney